TWI870440B - 活化素受體樣激酶抑制劑之鹽及晶體形式 - Google Patents

活化素受體樣激酶抑制劑之鹽及晶體形式 Download PDF

Info

Publication number
TWI870440B
TWI870440B TW109127433A TW109127433A TWI870440B TW I870440 B TWI870440 B TW I870440B TW 109127433 A TW109127433 A TW 109127433A TW 109127433 A TW109127433 A TW 109127433A TW I870440 B TWI870440 B TW I870440B
Authority
TW
Taiwan
Prior art keywords
salt
single crystal
crystal form
diffraction pattern
ray powder
Prior art date
Application number
TW109127433A
Other languages
English (en)
Chinese (zh)
Other versions
TW202120509A (zh
Inventor
克萊爾 孟登道
黛布拉 馬賽克
戈登 威爾基
喬許亞 Ｄ 威特茲格
布萊恩 海因瑞區
勞倫 麥凱克恩
史帝芬 Ｃ 約翰斯頓
多米尼克 席格
哈洛 奧莫
Original Assignee
美商纜圖藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商纜圖藥品公司 filed Critical 美商纜圖藥品公司
Publication of TW202120509A publication Critical patent/TW202120509A/zh
Application granted granted Critical
Publication of TWI870440B publication Critical patent/TWI870440B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW109127433A 2019-08-13 2020-08-12 活化素受體樣激酶抑制劑之鹽及晶體形式 TWI870440B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
US62/885,977 2019-08-13

Publications (2)

Publication Number Publication Date
TW202120509A TW202120509A (zh) 2021-06-01
TWI870440B true TWI870440B (zh) 2025-01-21

Family

ID=72193669

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109127433A TWI870440B (zh) 2019-08-13 2020-08-12 活化素受體樣激酶抑制劑之鹽及晶體形式

Country Status (14)

Country Link
US (1) US20220281879A1 (https=)
EP (1) EP4013757A1 (https=)
JP (2) JP7775186B2 (https=)
KR (1) KR20220052955A (https=)
CN (2) CN119638704A (https=)
BR (1) BR112022002597A2 (https=)
CA (1) CA3146701A1 (https=)
CO (1) CO2022001450A2 (https=)
IL (1) IL290482A (https=)
JO (1) JOP20220014A1 (https=)
MX (2) MX2022001741A (https=)
TW (1) TWI870440B (https=)
UA (1) UA130650C2 (https=)
WO (1) WO2021030386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311889B (zh) * 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181117A1 (en) * 2016-04-15 2017-10-19 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
TW201904958A (zh) * 2017-06-15 2019-02-01 美商百歐克斯製藥公司 含有咪唑之alk2激酶抑制劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181117A1 (en) * 2016-04-15 2017-10-19 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
TW201904958A (zh) * 2017-06-15 2019-02-01 美商百歐克斯製藥公司 含有咪唑之alk2激酶抑制劑

Also Published As

Publication number Publication date
JP2022544272A (ja) 2022-10-17
CN114222745A (zh) 2022-03-22
BR112022002597A2 (pt) 2022-07-05
CN114222745B (zh) 2025-03-25
CA3146701A1 (en) 2021-02-18
WO2021030386A1 (en) 2021-02-18
CO2022001450A2 (es) 2022-05-31
CN119638704A (zh) 2025-03-18
AU2020328534A1 (en) 2022-03-17
JP2025148406A (ja) 2025-10-07
EP4013757A1 (en) 2022-06-22
IL290482A (en) 2022-04-01
KR20220052955A (ko) 2022-04-28
JOP20220014A1 (ar) 2023-01-30
MX2024014312A (es) 2024-12-06
TW202120509A (zh) 2021-06-01
UA130650C2 (uk) 2026-04-08
JP7775186B2 (ja) 2025-11-25
US20220281879A1 (en) 2022-09-08
MX2022001741A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
TWI870440B (zh) 活化素受體樣激酶抑制劑之鹽及晶體形式
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
PT1912973E (pt) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5 trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
US20160122329A1 (en) Crystalline forms of afatinib di-maleate
JP2020514360A (ja) Ｍｋ２阻害剤の形態および組成物
US8802854B2 (en) Crystalline forms of Prasugrel salts
JP2023157909A (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
EP3430004B1 (en) Solid state forms of nilotinib salts
CN111094241B (zh) 一种氧代吡啶酰胺类衍生物的晶型及其制备方法
AU2020328534B2 (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
TW202339717A (zh) 用作激酶抑制劑的化合物及其應用
CA3246202A1 (en) CRYSTALLINE FORMS AND SALTS OF A PI3K INHIBITOR AND THEIR PROCESSES OF MANUFACTURE AND USE
HK40117473A (zh) 活化素受体样激酶抑制剂的盐和晶体形式
HK40069001B (zh) 活化素受体样激酶抑制剂的盐和晶体形式
HK40069001A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
BR112021001435A2 (pt) formas cristalinas de um inibidor de lta4h
WO2007012042A1 (en) New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide
WO2016081538A1 (en) Solid state forms of ceritinib and salts thereof
CN121241043A (zh) 埃维酰胺的晶型
WO2026008053A1 (zh) 补体因子b抑制剂的盐、其制备方法及用途
WO2026082074A1 (zh) Parg抑制剂的盐型、晶型及其组合物、制备方法和应用
JP2022515196A (ja) プロテインキナーゼ活性を阻害するためのアミノピリミジン系化合物
HK40025351A (en) Crystal form of oxopicolinamide derivative and preparation method therefor